Start-up biotech companies should be focus of NIDA collaborative drug research, ad hoc group recommends.
BIOTECH START-UPS SHOULD BE FOCUS OF NIDA COLLABORATIONS, Morton Goldberg, University of Pennsylvania, said at a March 8 meeting of the National Institute on Drug Abuse extramural science advisory board in Rockville, Md. NIDA should concentrate on "ways to enhance industry involvement, focusing on start-up biotech companies," Goldberg said. He was reporting recommendations from an ad hoc panel of consultants that met March 7 to assess NIDA's drug development program.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth